世界の直接作用型抗ウイルス薬市場規模・現状・予測2021-2027

【英語タイトル】Global Direct-acting Antiviral Drugs Market Size, Status and Forecast 2021-2027

QYResearchが出版した調査資料(QY21JNE2141)・商品コード:QY21JNE2141
・発行会社(調査会社):QYResearch
・発行日:2021年6月
・ページ数:108
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥510,900見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥766,350見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査資料では、直接作用型抗ウイルス薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(NS3 / 4Aプロテアーゼ阻害剤、ヌクレオシド&ヌクレオチドNS5Bポリメラーゼ阻害剤、NS5A阻害剤、非ヌクレオシドNS5Bポリメラーゼ阻害剤)、用途別市場規模(病院、診療所、外来手術センター、薬局、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・直接作用型抗ウイルス薬の市場動向
・企業の競争状況、市場シェア
・直接作用型抗ウイルス薬の種類別市場規模(NS3 / 4Aプロテアーゼ阻害剤、ヌクレオシド&ヌクレオチドNS5Bポリメラーゼ阻害剤、NS5A阻害剤、非ヌクレオシドNS5Bポリメラーゼ阻害剤)
・直接作用型抗ウイルス薬の用途別市場規模(病院、診療所、外来手術センター、薬局、その他)
・直接作用型抗ウイルス薬の北米市場規模2016-2027(アメリカ、カナダ)
・直接作用型抗ウイルス薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・直接作用型抗ウイルス薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・直接作用型抗ウイルス薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・直接作用型抗ウイルス薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(AbbVie Inc.、GSK、Boehringer Ingelheim、Merck、Novartis、Beximco Pharmaceuticals、Roche、Bristol-Myers Squibb Company、Gilead Sciences、Janssen (Johnson & Johnson)、Vertex Pharmaceuticals、Natco Pharma)
・結論
【レポートの概要】

Market Analysis and Insights: Global Direct-acting Antiviral Drugs Market
The global Direct-acting Antiviral Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Direct-acting Antiviral Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Direct-acting Antiviral Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Direct-acting Antiviral Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Direct-acting Antiviral Drugs market.

Global Direct-acting Antiviral Drugs Scope and Market Size
Direct-acting Antiviral Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Direct-acting Antiviral Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
NS3/4A Protease Inhibitors
Nucleoside and Nucleotide NS5B Polymerase Inhibitors
NS5A Inhibitors
Non-Nucleoside NS5B Polymerase Inhibitors

Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie Inc.
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Roche
Bristol-Myers Squibb Company
Gilead Sciences
Janssen (Johnson & Johnson)
Vertex Pharmaceuticals
Natco Pharma

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 NS3/4A Protease Inhibitors
1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
1.2.4 NS5A Inhibitors
1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors
1.3 Market by Application
1.3.1 Global Direct-acting Antiviral Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Direct-acting Antiviral Drugs Market Perspective (2016-2027)
2.2 Direct-acting Antiviral Drugs Growth Trends by Regions
2.2.1 Direct-acting Antiviral Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Direct-acting Antiviral Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Direct-acting Antiviral Drugs Industry Dynamic
2.3.1 Direct-acting Antiviral Drugs Market Trends
2.3.2 Direct-acting Antiviral Drugs Market Drivers
2.3.3 Direct-acting Antiviral Drugs Market Challenges
2.3.4 Direct-acting Antiviral Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue
3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2016-2021)
3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Direct-acting Antiviral Drugs Revenue
3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio
3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2020
3.5 Direct-acting Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Direct-acting Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Direct-acting Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Direct-acting Antiviral Drugs Breakdown Data by Type
4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2016-2021)
4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2022-2027)

5 Direct-acting Antiviral Drugs Breakdown Data by Application
5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2016-2021)
5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Direct-acting Antiviral Drugs Market Size (2016-2027)
6.2 North America Direct-acting Antiviral Drugs Market Size by Type
6.2.1 North America Direct-acting Antiviral Drugs Market Size by Type (2016-2021)
6.2.2 North America Direct-acting Antiviral Drugs Market Size by Type (2022-2027)
6.2.3 North America Direct-acting Antiviral Drugs Market Size by Type (2016-2027)
6.3 North America Direct-acting Antiviral Drugs Market Size by Application
6.3.1 North America Direct-acting Antiviral Drugs Market Size by Application (2016-2021)
6.3.2 North America Direct-acting Antiviral Drugs Market Size by Application (2022-2027)
6.3.3 North America Direct-acting Antiviral Drugs Market Size by Application (2016-2027)
6.4 North America Direct-acting Antiviral Drugs Market Size by Country
6.4.1 North America Direct-acting Antiviral Drugs Market Size by Country (2016-2021)
6.4.2 North America Direct-acting Antiviral Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Direct-acting Antiviral Drugs Market Size (2016-2027)
7.2 Europe Direct-acting Antiviral Drugs Market Size by Type
7.2.1 Europe Direct-acting Antiviral Drugs Market Size by Type (2016-2021)
7.2.2 Europe Direct-acting Antiviral Drugs Market Size by Type (2022-2027)
7.2.3 Europe Direct-acting Antiviral Drugs Market Size by Type (2016-2027)
7.3 Europe Direct-acting Antiviral Drugs Market Size by Application
7.3.1 Europe Direct-acting Antiviral Drugs Market Size by Application (2016-2021)
7.3.2 Europe Direct-acting Antiviral Drugs Market Size by Application (2022-2027)
7.3.3 Europe Direct-acting Antiviral Drugs Market Size by Application (2016-2027)
7.4 Europe Direct-acting Antiviral Drugs Market Size by Country
7.4.1 Europe Direct-acting Antiviral Drugs Market Size by Country (2016-2021)
7.4.2 Europe Direct-acting Antiviral Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2016-2027)
8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type
8.2.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application
8.3.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region
8.4.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Direct-acting Antiviral Drugs Market Size (2016-2027)
9.2 Latin America Direct-acting Antiviral Drugs Market Size by Type
9.2.1 Latin America Direct-acting Antiviral Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Direct-acting Antiviral Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Direct-acting Antiviral Drugs Market Size by Type (2016-2027)
9.3 Latin America Direct-acting Antiviral Drugs Market Size by Application
9.3.1 Latin America Direct-acting Antiviral Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Direct-acting Antiviral Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Direct-acting Antiviral Drugs Market Size by Application (2016-2027)
9.4 Latin America Direct-acting Antiviral Drugs Market Size by Country
9.4.1 Latin America Direct-acting Antiviral Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Direct-acting Antiviral Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2016-2027)
10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type
10.2.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application
10.3.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country
10.4.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction
11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.1.5 AbbVie Inc. Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Direct-acting Antiviral Drugs Introduction
11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.2.5 GSK Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction
11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Direct-acting Antiviral Drugs Introduction
11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Direct-acting Antiviral Drugs Introduction
11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Beximco Pharmaceuticals
11.6.1 Beximco Pharmaceuticals Company Details
11.6.2 Beximco Pharmaceuticals Business Overview
11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.6.5 Beximco Pharmaceuticals Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Direct-acting Antiviral Drugs Introduction
11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.7.5 Roche Recent Development
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Details
11.8.2 Bristol-Myers Squibb Company Business Overview
11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction
11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.8.5 Bristol-Myers Squibb Company Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction
11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.9.5 Gilead Sciences Recent Development
11.10 Janssen (Johnson & Johnson)
11.10.1 Janssen (Johnson & Johnson) Company Details
11.10.2 Janssen (Johnson & Johnson) Business Overview
11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction
11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.10.5 Janssen (Johnson & Johnson) Recent Development
11.11 Vertex Pharmaceuticals
11.11.1 Vertex Pharmaceuticals Company Details
11.11.2 Vertex Pharmaceuticals Business Overview
11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.11.5 Vertex Pharmaceuticals Recent Development
11.12 Natco Pharma
11.12.1 Natco Pharma Company Details
11.12.2 Natco Pharma Business Overview
11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction
11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2016-2021)
11.12.5 Natco Pharma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of NS3/4A Protease Inhibitors
Table 3. Key Players of Nucleoside and Nucleotide NS5B Polymerase Inhibitors
Table 4. Key Players of NS5A Inhibitors
Table 5. Key Players of Non-Nucleoside NS5B Polymerase Inhibitors
Table 6. Global Direct-acting Antiviral Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Direct-acting Antiviral Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Direct-acting Antiviral Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Direct-acting Antiviral Drugs Market Share by Regions (2016-2021)
Table 10. Global Direct-acting Antiviral Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Direct-acting Antiviral Drugs Market Share by Regions (2022-2027)
Table 12. Direct-acting Antiviral Drugs Market Trends
Table 13. Direct-acting Antiviral Drugs Market Drivers
Table 14. Direct-acting Antiviral Drugs Market Challenges
Table 15. Direct-acting Antiviral Drugs Market Restraints
Table 16. Global Direct-acting Antiviral Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Direct-acting Antiviral Drugs Market Share by Players (2016-2021)
Table 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Direct-acting Antiviral Drugs as of 2020)
Table 19. Ranking of Global Top Direct-acting Antiviral Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Direct-acting Antiviral Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Direct-acting Antiviral Drugs Product Solution and Service
Table 23. Date of Enter into Direct-acting Antiviral Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Direct-acting Antiviral Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. AbbVie Inc. Company Details
Table 64. AbbVie Inc. Business Overview
Table 65. AbbVie Inc. Direct-acting Antiviral Drugs Product
Table 66. AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 67. AbbVie Inc. Recent Development
Table 68. GSK Company Details
Table 69. GSK Business Overview
Table 70. GSK Direct-acting Antiviral Drugs Product
Table 71. GSK Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 72. GSK Recent Development
Table 73. Boehringer Ingelheim Company Details
Table 74. Boehringer Ingelheim Business Overview
Table 75. Boehringer Ingelheim Direct-acting Antiviral Drugs Product
Table 76. Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 77. Boehringer Ingelheim Recent Development
Table 78. Merck Company Details
Table 79. Merck Business Overview
Table 80. Merck Direct-acting Antiviral Drugs Product
Table 81. Merck Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 82. Merck Recent Development
Table 83. Novartis Company Details
Table 84. Novartis Business Overview
Table 85. Novartis Direct-acting Antiviral Drugs Product
Table 86. Novartis Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 87. Novartis Recent Development
Table 88. Beximco Pharmaceuticals Company Details
Table 89. Beximco Pharmaceuticals Business Overview
Table 90. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 91. Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 92. Beximco Pharmaceuticals Recent Development
Table 93. Roche Company Details
Table 94. Roche Business Overview
Table 95. Roche Direct-acting Antiviral Drugs Product
Table 96. Roche Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 97. Roche Recent Development
Table 98. Bristol-Myers Squibb Company Company Details
Table 99. Bristol-Myers Squibb Company Business Overview
Table 100. Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 101. Bristol-Myers Squibb Company Recent Development
Table 102. Gilead Sciences Company Details
Table 103. Gilead Sciences Business Overview
Table 104. Gilead Sciences Direct-acting Antiviral Drugs Product
Table 105. Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 106. Gilead Sciences Recent Development
Table 107. Janssen (Johnson & Johnson) Company Details
Table 108. Janssen (Johnson & Johnson) Business Overview
Table 109. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product
Table 110. Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 111. Janssen (Johnson & Johnson) Recent Development
Table 112. Vertex Pharmaceuticals Company Details
Table 113. Vertex Pharmaceuticals Business Overview
Table 114. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 115. Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 116. Vertex Pharmaceuticals Recent Development
Table 117. Natco Pharma Company Details
Table 118. Natco Pharma Business Overview
Table 119. Natco Pharma Direct-acting Antiviral Drugs Product
Table 120. Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 121. Natco Pharma Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Direct-acting Antiviral Drugs Market Share by Type: 2020 VS 2027
Figure 2. NS3/4A Protease Inhibitors Features
Figure 3. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Features
Figure 4. NS5A Inhibitors Features
Figure 5. Non-Nucleoside NS5B Polymerase Inhibitors Features
Figure 6. Global Direct-acting Antiviral Drugs Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Pharmacies Case Studies
Figure 11. Others Case Studies
Figure 12. Direct-acting Antiviral Drugs Report Years Considered
Figure 13. Global Direct-acting Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Direct-acting Antiviral Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Direct-acting Antiviral Drugs Market Share by Regions: 2020 VS 2027
Figure 16. Global Direct-acting Antiviral Drugs Market Share by Regions (2022-2027)
Figure 17. Global Direct-acting Antiviral Drugs Market Share by Players in 2020
Figure 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Direct-acting Antiviral Drugs as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2020
Figure 20. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2016-2021)
Figure 21. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2022-2027)
Figure 22. North America Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Direct-acting Antiviral Drugs Market Share by Type (2016-2027)
Figure 24. North America Direct-acting Antiviral Drugs Market Share by Application (2016-2027)
Figure 25. North America Direct-acting Antiviral Drugs Market Share by Country (2016-2027)
Figure 26. United States Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Direct-acting Antiviral Drugs Market Share by Type (2016-2027)
Figure 30. Europe Direct-acting Antiviral Drugs Market Share by Application (2016-2027)
Figure 31. Europe Direct-acting Antiviral Drugs Market Share by Country (2016-2027)
Figure 32. Germany Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Region (2016-2027)
Figure 42. China Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Direct-acting Antiviral Drugs Market Share by Type (2016-2027)
Figure 50. Latin America Direct-acting Antiviral Drugs Market Share by Application (2016-2027)
Figure 51. Latin America Direct-acting Antiviral Drugs Market Share by Country (2016-2027)
Figure 52. Mexico Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Country (2016-2027)
Figure 58. Turkey Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. AbbVie Inc. Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 62. GSK Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 63. Boehringer Ingelheim Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 66. Beximco Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 67. Roche Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 68. Bristol-Myers Squibb Company Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 69. Gilead Sciences Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 70. Janssen (Johnson & Johnson) Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 71. Vertex Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 72. Natco Pharma Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed


★調査レポート[世界の直接作用型抗ウイルス薬市場規模・現状・予測2021-2027] (コード:QY21JNE2141)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の直接作用型抗ウイルス薬市場規模・現状・予測2021-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆